LeonaBio (LONA) Liabilities and Shareholders Equity (2019 - 2026)

LeonaBio (LONA) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $71.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 64.53% year-over-year to $71.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229.3 million (down 23.51% YoY) and the FY2025 annual result came in at $92.2 million, up 56.78% from the prior year.
• Liabilities and Shareholders Equity declined to $71.6 million in Q1 2026 per LONA's latest filing, from $92.2 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $313.0 million in Q1 2022 and bottomed at $30.0 million in Q3 2025.
• The 5-year median for Liabilities and Shareholders Equity is $133.5 million (2024), against an average of $152.1 million.
• The widest annual swing landed in 2025, when Liabilities and Shareholders Equity slumped 68.05%; it then jumped 64.53% in 2026.
• Tracing LONA's Liabilities and Shareholders Equity over 5 years: stood at $258.2 million in 2022, then tumbled by 37.93% to $160.2 million in 2023, then slumped by 63.32% to $58.8 million in 2024, then jumped by 56.78% to $92.2 million in 2025, then decreased by 22.31% to $71.6 million in 2026.
• Per Business Quant, the three latest LONA Liabilities and Shareholders Equity figures stand at $71.6 million (Q1 2026), $92.2 million (Q4 2025), and $30.0 million (Q3 2025).

Peer Comparison